688 related articles for article (PubMed ID: 18362931)
21. IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy.
Alters SE; Gadea JR; Holm B; Lebkowski J; Philip R
J Immunother; 1999 May; 22(3):229-36. PubMed ID: 10335482
[TBL] [Abstract][Full Text] [Related]
22. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
[TBL] [Abstract][Full Text] [Related]
23. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
24. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia.
Chen X; Regn S; Raffegerst S; Kolb HJ; Roskrow M
Br J Haematol; 2000 Nov; 111(2):596-607. PubMed ID: 11122108
[TBL] [Abstract][Full Text] [Related]
25. Recent progress in GM-CSF-based cancer immunotherapy.
Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
[TBL] [Abstract][Full Text] [Related]
26. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
27. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
28. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
30. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
[TBL] [Abstract][Full Text] [Related]
31. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.
Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J
Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666
[TBL] [Abstract][Full Text] [Related]
32. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
[TBL] [Abstract][Full Text] [Related]
33. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532
[TBL] [Abstract][Full Text] [Related]
34. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma.
Triozzi PL; Kim J; Aldrich W
J Hematother Stem Cell Res; 2003 Jun; 12(3):279-87. PubMed ID: 12857369
[TBL] [Abstract][Full Text] [Related]
35. Induction of a tumour-specific CTL response by exosomes isolated from heat-treated malignant ascites of gastric cancer patients.
Zhong H; Yang Y; Ma S; Xiu F; Cai Z; Zhao H; Du L
Int J Hyperthermia; 2011; 27(6):604-11. PubMed ID: 21846196
[TBL] [Abstract][Full Text] [Related]
36. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells.
Dai S; Zhou X; Wang B; Wang Q; Fu Y; Chen T; Wan T; Yu Y; Cao X
J Mol Med (Berl); 2006 Dec; 84(12):1067-76. PubMed ID: 17016692
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
38. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
39. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells.
Alters SE; Gadea JR; Philip R
Adv Exp Med Biol; 1997; 417():519-24. PubMed ID: 9286413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
